Results 81 to 90 of about 401,465 (309)
Simultaneous occurrence of advanced neuroblastoma and acute lymphoblastic leukemia: a case report [PDF]
, 2011 Neuroblastoma is the most common extracranial solid tumor in children. The cooccurrence of neuroblastoma and acute lymphoblastic leukemia is rare. We report a rare case of advanced-stage neuroblastoma in a 3.5-year-old girl that was accompanied by ...
Fekri, Kiavash. +4 more
core +1 more source
CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition. [PDF]
, 2019 Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a genetically heterogeneous subtype of B-cell ALL characterized by chromosomal rearrangements and mutations that result in aberrant cytokine receptor and kinase signaling.
Delgado-Martin, Cristina +5 more
core +2 more sources
The Expression Level of CCDC26 and FOXCUT Genes in Acute Lymphoblastic Leukemia [PDF]
, 2021 Background and Aim: Acute lymphoblastic leukemia (ALL) is a malignant disease of lymphoid progenitor cells affecting both children and adults. Long non-coding RNAs (lncRNAs) are one kind of non-coding RNAs (ncRNAs), reported modulating the initiation or ...
Barati, Samaneh +3 more
core +2 more sources
T-cell acute lymphoblastic leukemia [PDF]
Hematology, 2016 Abstract T-cell acute lymphoblastic leukemia (T-ALL) is biologically distinct from its B lymphoblastic (B-ALL) counterpart and shows different kinetic patterns of disease response. Although very similar regimens are used to treat T-ALL and B-ALL, distinctions in response to different elements of therapy have been observed.
David T. Teachey, Elizabeth A. Raetz
openaire +3 more sources
Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia [PDF]
, 2015 Several chemo-resistance mechanisms including the Bcl-2 protein family overexpression and constitutive activation of the PI3K/Akt/mTOR signaling have been documented in acute lymphoblastic leukemia (ALL), encouraging targeted approaches to circumvent ...
ALLEGRETTI, MATTEO +12 more
core +1 more source
Pharmacogenetics in Acute Lymphoblastic Leukemia [PDF]
Seminars in Hematology, 2009 Progress in the treatment of acute lymphoblastic leukemia (ALL) in children has been remarkable, from a disease being lethal four decades ago to current cure rates exceeding 80%. This exemplary progress is largely due to the optimization of existing treatment modalities rather than the discovery of new antileukemic agents.
William E. Evans +3 more
openaire +3 more sources
Cancer, 2019 Inotuzumab ozogamicin (InO) is an antibody‐drug conjugate used for adults with relapsed/refractory B‐cell precursor (BCP) acute lymphoblastic leukemia (ALL).
H. Kantarjian +12 more
semanticscholar +1 more source
Correlation between malondialdehyde and metanephrine in patients with acute lymphoblastic leukemia [PDF]
, 2014 Acute lymphoblastic leukemia (ALL) is one of the most common diseases , so in this study the serum level of malondialdehyde and its relationship with metanephrine was investigated in acute lymphoblastic leukemia patients over one month of treatment. Some
Zainulabdeen, Jwan A.
core +2 more sources
Bayesian modelling of response to therapy and drug-sensitivity in acute lymphoblastic leukemia [PDF]
arXiv, 2023 Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic malignancy involving the abnormal proliferation of immature lymphocytes, accounting for most pediatric cancer cases. ALL management in children has seen great improvement in the last decades thanks to better understanding of the disease leading to improved treatment strategies evidenced ...
arxiv
Journal of Medical Case Reports, 2022 Background There have hardly been any reported cases of children presenting with Kaposi sarcoma as a second malignancy following treatment for acute lymphoblastic leukemia outside a transplant setting.
Richard Nyeko +3 more
doaj +1 more source